185 related articles for article (PubMed ID: 33206598)
21. Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Smith TJ
N Engl J Med; 2021 Mar; 384(12):1175. PubMed ID: 33761223
[No Abstract] [Full Text] [Related]
22. Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Biswas B; Ganguly S; Ghosh J
N Engl J Med; 2021 Mar; 384(12):1174-1175. PubMed ID: 33761222
[No Abstract] [Full Text] [Related]
23. Olaparib in Metastatic Castration-Resistant Prostate Cancer.
McCaw ZR; Liu MA; Wei LJ
N Engl J Med; 2021 Mar; 384(12):1174. PubMed ID: 33761221
[No Abstract] [Full Text] [Related]
24. Olaparib in Metastatic Castration-Resistant Prostate Cancer. Reply.
Hussain M; Desai C; de Bono J
N Engl J Med; 2021 Mar; 384(12):1175-1176. PubMed ID: 33761224
[No Abstract] [Full Text] [Related]
25. PARP inhibition in BRCA2-mutated prostate cancer.
Nientiedt C; Tolstov Y; Volckmar AL; Endris V; Bonekamp D; Haberkorn U; Jäger D; Sültmann H; Stenzinger A; Hohenfellner M; Grüllich C; Duensing S
Ann Oncol; 2017 Jan; 28(1):189-191. PubMed ID: 27687312
[No Abstract] [Full Text] [Related]
26. Re: Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Taneja SS
J Urol; 2020 Oct; 204(4):877-878. PubMed ID: 32716237
[No Abstract] [Full Text] [Related]
27. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
Karzai F; VanderWeele D; Madan RA; Owens H; Cordes LM; Hankin A; Couvillon A; Nichols E; Bilusic M; Beshiri ML; Kelly K; Krishnasamy V; Lee S; Lee MJ; Yuno A; Trepel JB; Merino MJ; Dittamore R; Marté J; Donahue RN; Schlom J; Killian KJ; Meltzer PS; Steinberg SM; Gulley JL; Lee JM; Dahut WL
J Immunother Cancer; 2018 Dec; 6(1):141. PubMed ID: 30514390
[TBL] [Abstract][Full Text] [Related]
28. Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.
Zhu J; Tucker M; Wang E; Grossman JS; Armstrong AJ; George DJ; Zhang T
Clin Genitourin Cancer; 2017 Dec; 15(6):e1137-e1141. PubMed ID: 28780018
[No Abstract] [Full Text] [Related]
29. Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452-8.
Liang J; Beckta JM; Bindra RS
Eur Urol; 2019 Oct; 76(4):e109-e110. PubMed ID: 31080125
[No Abstract] [Full Text] [Related]
30. Re: Matthew R. Smith, Maha Hussain, Fred Saad, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386:1132-1142.
Di Lorenzo G; Buonerba C
Eur Urol; 2022 Jul; 82(1):e17. PubMed ID: 35393160
[No Abstract] [Full Text] [Related]
31. Re: Olaparib Combined with Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial.
Taneja SS
J Urol; 2019 Apr; 201(4):667. PubMed ID: 30653001
[No Abstract] [Full Text] [Related]
32. Olaparib for Metastatic Castration-Resistant Prostate Cancer. Reply.
de Bono J; Kang J; Hussain M
N Engl J Med; 2020 Aug; 383(9):891. PubMed ID: 32846073
[No Abstract] [Full Text] [Related]
33. Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Heidegger I; Pircher A
N Engl J Med; 2020 Aug; 383(9):890-891. PubMed ID: 32846072
[No Abstract] [Full Text] [Related]
34. Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Mutetwa T; Foulkes WD; Polak P
N Engl J Med; 2020 Aug; 383(9):890. PubMed ID: 32846071
[No Abstract] [Full Text] [Related]
35. Efficacy and safety profile of olaparib for patients with metastatic castration-resistant prostate cancer: A preliminary report of real-world data in a single institution in Japan.
Yasuda Y; Sakurai M; Numao N; Yamamoto S; Yonese J; Yuasa T
Int J Urol; 2023 Nov; 30(11):1060-1062. PubMed ID: 37493076
[No Abstract] [Full Text] [Related]
36. Targeting NPRL2 to enhance the efficacy of Olaparib in castration-resistant prostate cancer.
Chen X; Chen Z; Zheng B; Tang W
Biochem Biophys Res Commun; 2019 Jan; 508(2):620-625. PubMed ID: 30522863
[TBL] [Abstract][Full Text] [Related]
37. Olaparib for DNA repair-deficient prostate cancer - one for all, or all for one?
Antonarakis ES
Nat Rev Clin Oncol; 2020 Aug; 17(8):455-456. PubMed ID: 32447344
[No Abstract] [Full Text] [Related]
38. Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer.
Considine B; Petrylak DP
Oncology (Williston Park); 2019 Apr; 33(4):128-31. PubMed ID: 30990564
[TBL] [Abstract][Full Text] [Related]
39. Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.02.013.
Mehra N; Dolling D; de Bono J
Eur Urol; 2018 Sep; 74(3):e69-e70. PubMed ID: 29866468
[No Abstract] [Full Text] [Related]
40. Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).
Hussain M; Corcoran C; Sibilla C; Fizazi K; Saad F; Shore N; Sandhu S; Mateo J; Olmos D; Mehra N; Kolinsky MP; Roubaud G; Özgüroǧlu M; Matsubara N; Gedye C; Choi YD; Padua C; Kohlmann A; Huisden R; Elvin JA; Kang J; Adelman CA; Allen A; Poehlein C; de Bono J
Clin Cancer Res; 2022 Apr; 28(8):1518-1530. PubMed ID: 35091440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
